key: cord-0828935-mmt13tyf authors: Ceriello, Antonio title: Diabetes, SARS-CoV-2/COVID-19 vaccines and glycemic control: call for data date: 2021-03-05 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2021.108741 sha: ee493fe3bb911a5160307b614a9c656887b91b5c doc_id: 828935 cord_uid: mmt13tyf nan Immuno-response. The prognosis of people with diabetes affected by COVID-19 is particularly bad (1). There are several possible pathophysiological explanations, including the direct damaging effect of hyperglycemia (2), but, certainly, and hampered immune response, often present in this population, also plays a key role (3) (4) . This reality raises the claim for prioritizing the vaccination against SARS-CoV-2/COVID-19 in people with diabetes (5). The question, however, might be more complex. The goal of the vaccination is to obtain a sustained and effective immune response. In the case of diabetes the data is controversial, suggesting that not always this result is obtained (6) (7) . Evidence suggests that the glycemic control has a strong impact on the efficiency of the immune response (8) (9) . Therefore, it seems reasonable wondering whether it is not appropriate to improve glycemic control before administering the vaccine to optimize the response to it. Data is needed not to waste this important opportunity to get out of the pandemic for people with diabetes. COVID-19 in people living with diabetes: An international consensus Hyperglycemia and COVID-19: What was known and what is really new? Type 2 diabetes and viral infection; cause and effect of disease COVID-19 vaccine prioritisation for type 1 and type 2 diabetes Benefits of flu vaccination for persons with diabetes mellitus: A review Posthoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans High glucose concentration impairs ATP outflow and immunoglobulin production by human peripheral B lymphocytes: involvement of P2X7 receptor Conflict of Interest: AC does not have conflicts of interest to declare.